Global Cord Blood (NYSE:CO) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Global Cord Blood (NYSE:COFree Report) in a research report released on Wednesday. The brokerage issued a strong-buy rating on the medical research company’s stock.

Global Cord Blood Stock Performance

Shares of NYSE CO opened at $1.35 on Wednesday. Global Cord Blood has a 12-month low of $2.03 and a 12-month high of $5.50. The stock has a market cap of $164.09 million, a PE ratio of 2.11 and a beta of 0.16. The company has a 50-day moving average of $1.52 and a 200 day moving average of $1.35.

Institutional Trading of Global Cord Blood

Several large investors have recently bought and sold shares of CO. Moneta Group Investment Advisors LLC grew its stake in shares of Global Cord Blood by 99,844.5% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 26,093,520 shares of the medical research company’s stock valued at $77,957,000 after buying an additional 26,067,412 shares during the period. Northern Trust Corp purchased a new stake in shares of Global Cord Blood in the 2nd quarter valued at approximately $96,000. Finally, Natixis Advisors L.P. grew its stake in shares of Global Cord Blood by 6.6% in the 1st quarter. Natixis Advisors L.P. now owns 189,330 shares of the medical research company’s stock valued at $729,000 after buying an additional 11,709 shares during the period.

Global Cord Blood Company Profile

(Get Free Report)

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.

Featured Articles

Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.